Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › AL › Huntsville › NPI 1447221056
Hospital

The Health Care Authority of the City of Huntsville

The Health Care Authority of the City of Huntsville was paid $17.76M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.

33Billing provider infoTHE HEALTH CARE AUTHORITY OF THE CITY OF HUNTSVILLE
HUNTSVILLE, AL 35801
33aNPI1447221056assigned 01/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.76M
24GClaims721,233
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Alabama

Rank by total paid#2 of 77
Median peer was paid$1.13M
This provider vs. median16×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018117,893$2.38M
2019127,103$2.57M
202083,666$1.77M
202198,269$2.36M
2022106,182$2.61M
2023108,082$3.52M
2024incomplete80,038$2.54M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 22% 55,913 52,898 $3.95M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 20% 82,116 78,791 $3.52M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 9.6% 60,501 54,570 $1.71M
99282 Emergency department visit for the evaluation and management, low to moderate severity 5.2% 23,856 22,551 $929K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 3.5% 2,851 2,779 $624K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.5% 70,611 64,198 $618K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 3.2% 10,979 10,484 $575K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 2.8% 1,858 1,759 $490K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 1.7% 1,180 1,060 $298K
80053 Comprehensive metabolic panel 1.5% 21,221 18,896 $272K
64493 1.4% 3,261 2,065 $253K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1.4% 5,050 4,945 $249K
180 more codes
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 1.3% 17,867 $231K
86780 1.2% 12,536 $212K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.1% 4,602 $195K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.1% 8,492 $191K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.0% 7,752 $179K
80048 Basic metabolic panel (calcium, ionized) <1% 21,817 $174K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 9,556 $160K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 3,394 $155K
87086 Culture, bacterial; quantitative colony count, urine <1% 12,877 $140K
71046 Radiologic examination, chest; 2 views <1% 11,081 $136K
88142 <1% 6,138 $135K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 3,651 $129K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 627 $108K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 6,334 $106K
87581 <1% 2,851 $105K
87486 <1% 2,851 $105K
64483 <1% 1,122 $93K
81003 <1% 30,816 $90K
86762 <1% 4,659 $90K
87070 <1% 6,957 $85K
87340 <1% 6,297 $80K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 160 $72K
81025 <1% 16,524 $54K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 3,849 $51K
86803 <1% 3,307 $49K
74018 <1% 4,358 $49K
84443 Thyroid stimulating hormone (TSH) <1% 2,822 $48K
62323 <1% 733 $45K
87081 <1% 4,455 $40K
83036 Hemoglobin; glycosylated (A1C) <1% 2,956 $39K
86850 <1% 5,996 $37K
76770 <1% 1,032 $34K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 1,679 $31K
82950 <1% 4,594 $30K
85045 <1% 5,061 $30K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,148 $29K
0002A <1% 777 $27K
82803 <1% 838 $27K
27096 <1% 177 $27K
G0378 Hospital observation service, per hour <1% 367 $27K
70450 Computed tomography, head or brain; without contrast material <1% 264 $26K
0001A <1% 1,018 $26K
86696 <1% 1,434 $23K
86695 <1% 1,431 $22K
95816 <1% 650 $21K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 695 $20K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 494 $20K
83020 <1% 1,175 $18K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 8,885 $17K
42820 Tonsillectomy and adenoidectomy; younger than age 12 <1% 43 $17K
86900 <1% 5,919 $17K
86901 <1% 5,919 $17K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 1,003 $16K
87400 <1% 2,680 $15K
82728 <1% 1,146 $14K
87077 <1% 1,706 $13K
83615 <1% 2,097 $13K
87420 <1% 807 $13K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 329 $11K
83605 <1% 889 $11K
84439 <1% 1,071 $10K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 391 $10K
80061 Lipid panel <1% 551 $10K
83550 <1% 747 $10K
93296 <1% 962 $9K
87088 <1% 851 $9K
80076 <1% 1,464 $9K
83655 <1% 516 $8K
87210 <1% 1,360 $8K
86140 <1% 3,295 $8K
83735 <1% 835 $8K
85014 <1% 2,453 $7K
82330 <1% 820 $7K
85018 <1% 2,202 $7K
83540 <1% 784 $7K
86694 <1% 429 $7K
82731 <1% 84 $6K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 587 $6K
84100 <1% 1,134 $6K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 142 $5K
82553 <1% 497 $5K
69436 Tympanostomy (requiring insertion of ventilating tube), general anesthesia <1% 27 $5K
83690 <1% 872 $5K
85610 <1% 1,139 $5K
84484 <1% 781 $5K
62264 <1% 70 $5K
82607 <1% 234 $5K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 168 $5K
0071A <1% 130 $5K
82947 <1% 1,261 $5K
84702 <1% 362 $4K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 230 $4K
0072A <1% 140 $4K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 5,373 $4K
64490 <1% 52 $4K
0004A <1% 97 $4K
82550 <1% 532 $3K
85027 <1% 606 $3K
59025 Fetal non-stress test <1% 631 $3K
84481 <1% 165 $3K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 15 $3K
87040 <1% 210 $2K
93880 <1% 50 $2K
84550 <1% 306 $2K
62370 <1% 28 $2K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 16 $2K
83021 <1% 107 $2K
84144 <1% 93 $1K
A9576 Injection, gadoteridol, (prohance multipack), per ml <1% 245 $1K
87186 <1% 126 $1K
86738 <1% 61 $1K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 84 $1K
62321 <1% 12 $976.71
76801 <1% 39 $943.60
62369 <1% 12 $871.56
71045 Radiologic examination, chest; single view <1% 323 $865.39
J7030 Infusion, normal saline solution , 1000 cc <1% 1,093 $846.82
83516 <1% 188 $844.24
82670 <1% 27 $834.73
85660 <1% 172 $803.82
82570 <1% 131 $786.24
85730 <1% 433 $752.74
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 13 $688.72
84295 <1% 230 $661.78
84132 <1% 228 $661.78
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 822 $644.97
90686 <1% 46 $608.96
82784 <1% 151 $589.56
J7120 Ringers lactate infusion, up to 1000 cc <1% 6,079 $579.92
84681 <1% 44 $579.80
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,738 $573.18
84156 <1% 131 $525.33
84466 <1% 16 $372.60
J2704 Injection, propofol, 10 mg <1% 10,753 $272.58
85652 <1% 69 $251.21
J1030 Injection, methylprednisolone acetate, 40 mg <1% 6,346 $206.74
74019 <1% 12 $197.23
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 365 $183.77
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 210 $138.68
82248 <1% 29 $133.90
82247 <1% 29 $126.10
80069 <1% 15 $115.57
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 391 $109.68
G2066 Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results <1% 85 $96.93
J1040 Injection, methylprednisolone acetate, 80 mg <1% 792 $92.05
82565 <1% 39 $75.31
J1644 Injection, heparin sodium, per 1000 units <1% 468 $73.20
96361 Intravenous infusion, hydration; each additional hour <1% 580 $71.93
96375 Therapeutic injection; each additional sequential IV push <1% 121 $68.00
36415 Collection of venous blood by venipuncture <1% 2,114 $65.24
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 67 $50.00
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 146 $49.90
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,366 $43.32
J3010 Injection, fentanyl citrate, 0.1 mg <1% 3,495 $37.09
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 11,678 $36.83
82962 <1% 1,077 $34.67
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 13 $24.00
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 508 $20.30
82435 <1% 14 $16.77
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 510 $11.21
P9612 Catheterization for collection of specimen, single patient, all places of service <1% 1,097 $10.59
88304 <1% 98 $8.53
J0690 Injection, cefazolin sodium, 500 mg <1% 65 $0.77
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 105 $0.06
64491 0% 52 $0.00
64495 0% 2,465 $0.00
82948 0% 101 $0.00
J3370 Injection, vancomycin hcl, 500 mg 0% 18 $0.00
69210 0% 18 $0.00
G0260 Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography 0% 13 $0.00
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 0% 59 $0.00
64494 0% 2,789 $0.00
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg 0% 296 $0.00
81511 0% 1,067 $0.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 186 $0.00
J1597 Injection, glycopyrrolate (glyrx-pf), 0.1 mg 0% 12 $0.00
88342 0% 35 $0.00
64492 0% 17 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 14 $0.00
A9270 Non-covered item or service 0% 29 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCRAWFORD, ROB (EXECUTIVE DIRECTOR, PFS)